Celldex Therapeutics
CLDX · NASDAQ
$30.29+$0.62 (+2.09%)TodayMarket closed ·
Prev close $29.67
EPS: actual vs estimate
Beat the estimate in 4 of the last 8 quarters, by 6.8% on average
Next report: , after the market closes
- Quarter
- Q3 FY26
- EPS estimate
- -$1.01
- Revenue estimate
- $1.01M
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | -$1.08 | -$0.94 | +12.8% |
| Q1 FY26 | -$1.16 | -$1.18 | −1.6% |
| Q4 FY25 | -$1.03 | -$1.22 | −18.6% |
| Q3 FY25 | -$0.9187 | -$1.01 | −9.9% |
| Q2 FY25 | -$0.8729 | -$0.85 | +2.6% |
| Q1 FY25 | -$0.7701 | -$0.81 | −5.2% |
| Q4 FY24 | -$0.749 | -$0.71 | +5.2% |
| Q3 FY24 | -$0.686 | -$0.64 | +6.7% |
Earnings calls
- Special Call - Celldex Therapeutics, Inc.
- Special Call - Celldex Therapeutics, Inc.
- Leerink Global Healthcare Conference 2026
- TD Cowen 46th Annual Health Care Conference
- Morgan Stanley 23rd Annual Global Healthcare Conference
- Special Call - Celldex Therapeutics, Inc.
- Special Call - Celldex Therapeutics, Inc.
- Special Call - Celldex Therapeutics, Inc.
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.